Latest news with #Vogenx
Associated Press
15-04-2025
- Health
- Associated Press
Vogenx, Inc. to Present Phase 2 Clinical Data on Mizagliflozin at the Endocrine Society (ENDO) 2025 Annual Conference
Data from Phase 2 Trial VGX-001-012 of Mizagliflozin in Post Bariatric Hypoglycemia will be Presented RALEIGH, NC / ACCESS Newswire / April 15, 2025 / Vogenx, Inc., a clinical-stage developer of novel therapeutics for the treatment of serious metabolic and gastrointestinal diseases, today announced that it will present phase 2 clinical data from Study VGX-001-012 (NCT05721729) at the Endocrine Society (ENDO) 2025 Annual Conference highlighting Mizagliflozin's effect on hypoglycemic events and relevant pharmacodynamic indicators in patients diagnosed with post bariatric hypoglycemia (PBH). Vogenx will present the data during an oral presentation during the ENDO 2025 Conference which will take place July 12-15, 2025 in San Francisco, California. Abstract Number: 3890 Title: Efficacy and Safety of the SGLT1 Inhibitor Mizagliflozin in Patients with Post-Bariatric Hypoglycemia Presentation Type: Oral Session Date & Time: Saturday Jul 12, 2025; 1:45 PM - 3:15 PM Location: Moscone Convention Center, 747 Howard St, San Francisco, CA 94103 Additional details will be made available prior to the Conference. About Mizagliflozin Mizagliflozin is an investigational first-in-class, oral, small molecule drug candidate that reduces postprandial glucose absorption, secretion of insulin, and secretion of gastric inhibitory peptide, also known as glucose-dependent insulinotropic peptide (GIP). The molecule is being developed by Vogenx for the treatment of PBH and gastroparesis, both debilitating diseases with high unmet medical need in underserved patient populations. Mizagliflozin has shown statistically significant reductions in Level 3 hypoglycemia events, postprandial glucose absorption as well as secretion of insulin and GIP in patients diagnosed with PBH. About Post-Bariatric Hypoglycemia PBH is an increasingly recognized chronic side effect of bariatric surgeries that are commonly performed as a treatment for obesity and related comorbidities. Neuroglycopenic symptoms can include shakiness, dizziness, confusion, sweating and loss of consciousness. These symptoms can debilitate with a significant negative impact on quality of life, can dangerously impair normal day-to-day activities and can be life-threatening. Bariatric surgery has proven to be the most effective treatment for severe obesity, leading to significant improvements in body mass index and obesity-related co-morbidities. It is estimated that over 9% of the U.S. population has a body mass index above 40 which is considered severely obese. With over 250,000 bariatric surgery procedures performed per year in the United States, postoperative prevalence of hypoglycemia symptoms in bariatric surgery patients is thought to be as high as 38.5%. There are currently no therapeutics approved by the FDA for the treatment of PBH. About Vogenx, Inc. Vogenx, Inc. is a clinical-stage life science company based in Raleigh, North Carolina. Vogenx is focused on developing novel therapeutics for the treatment of serious metabolic and gastrointestinal diseases with high unmet medical need. The company is developing Mizagliflozin for post bariatric hypoglycemia and gastroparesis. For more information about Vogenx, please visit For more information: +1 919.659.5677 [email protected] SOURCE: Vogenx, Inc. press release
Globe and Mail
11-02-2025
- Health
- Globe and Mail
Vogenx, Eiger BioPharmaceuticals, expected to drive market
The Post-Bariatric Hypoglycemia market growth is driven by factors like increase in the prevalence of Post-Bariatric Hypoglycemia, investments in research and development, entry of emerging therapies during the study period 2020-2034. The Post-Bariatric Hypoglycemia market report also offers comprehensive insights into the Post-Bariatric Hypoglycemia market size, share, Post-Bariatric Hypoglycemia epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Post-Bariatric Hypoglycemia market size growth forward. Some of the key highlights from the Post-Bariatric Hypoglycemia Market Insights Report: Several key pharmaceutical companies, including Vogenx, Eiger BioPharmaceuticals, and others, are developing novel products to improve the Post-Bariatric Hypoglycemia treatment outlook. In 2023, the United States represented approximately 90% of the total market for Post-Bariatric Hypoglycemia (PBH) across the seven major markets. PBH refers to the occurrence of low blood sugar following bariatric surgery, such as gastric bypass or sleeve gastrectomy, typically manifesting within a few years after the procedure. Key risk factors for PBH include rapid weight loss, changes in gastrointestinal anatomy, heightened insulin sensitivity, hyperinsulinemia, and reactive hypoglycemia. In 2023, there were roughly 100,000 cases of PBH across the 7MM, with the United States reporting the highest number of cases, followed by France. As bariatric surgery continues to be the most effective treatment for severe obesity, leading to improvements in body mass index and related co-morbidities, the prevalence of hypoglycemia symptoms after surgery is also on the rise in the U.S. The pathophysiology of PBH is complex, involving multiple interconnected mechanisms, believed to result from changes in the body's hormonal and metabolic response to food intake after bariatric surgery. Diagnosing PBH requires clinical evaluation, a review of the patient's medical history, blood glucose monitoring, and ruling out other potential causes of hypoglycemia. Additional diagnostic tests, such as mixed meal tolerance tests, continuous glucose monitoring, and pancreatic imaging, may also be employed. Managing PBH typically includes dietary adjustments, such as eating small, frequent meals, avoiding high-glycemic foods, and limiting simple sugars. Medications like acarbose, diazoxide, or GLP-1 receptor agonists may be prescribed to help regulate blood sugar levels. In severe cases, surgical interventions, such as partial or full reversal of the bariatric surgery, might be considered. While there are currently no FDA-approved treatments for PBH, several therapies are under investigation. Notable companies in the development of PBH treatments include Vogenx (with mizagliflozin) and Eiger BioPharmaceuticals (with avexitide). In April 2024, Vogenx announced the completion of dosing for the last patient in its Phase II clinical trial, VGX-001-012, which evaluates mizagliflozin for the treatment of post-bariatric hypoglycemia. As per DelveInsight analysis, the Post-Bariatric Hypoglycemia market is anticipated to witness growth at a considerable CAGR Strategise your business goals by understanding market dynamics @ Post-Bariatric Hypoglycemia Market Landscape Post-Bariatric Hypoglycemia Overview Post-Bariatric Hypoglycemia is an increasingly recognized complication following bariatric surgeries like Roux-en-Y gastric bypass (RYGB) and vertical sleeve gastrectomy (SG). Also known as reactive hypoglycemia or late dumping syndrome, this condition is a metabolic issue where a rise in blood glucose after eating triggers excessive insulin secretion, resulting in low blood sugar. Diagnosing Post-Bariatric Hypoglycemia involves a combination of clinical assessment, reviewing the patient's medical history, blood glucose monitoring, and excluding other potential causes of hypoglycemia. Additional diagnostic tests, such as mixed meal tolerance tests, continuous glucose monitoring, and pancreatic imaging, may also be used. Acarbose is commonly used as a first-line treatment, although its effectiveness is limited by gastrointestinal side effects. Diazoxide and octreotide have also been tried with varying results, but their side effects and the potential for poor patient adherence limit their use. Notably, exogenous GLP-1 receptor agonists have shown promise in improving PBH, likely by reducing insulin secretion from β-cells and increasing glucagon release from α-cells during hypoglycemic episodes. While surgical interventions were historically more common, such as gastrostomy tube placement, reversal of gastric bypass anatomy, and distal pancreatectomy, other treatments like calcium channel blockers (CCBs), including nifedipine or verapamil, can help bridge the gap between dietary management and surgery. Do you know the treatment paradigms for different countries? Download our Post-Bariatric Hypoglycemia Market Sample Report Post-Bariatric Hypoglycemia Epidemiology Insights In 2023, the United States reported the highest number of Post-Bariatric Hypoglycemia cases, accounting for approximately 80% of the total. According to DelveInsight's analysis, the majority of these cases occurred in patients who underwent sleeve gastrectomy, followed by those who had Roux-en-Y gastric bypass procedures, with other types of surgeries accounting for the remaining cases. Post-Bariatric Hypoglycemia Epidemiology Segmentation DelveInsight's Post-Bariatric Hypoglycemia market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Post-Bariatric Hypoglycemia historical patient pools and forecasted Post-Bariatric Hypoglycemia patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Post-Bariatric Hypoglycemia Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into: Visit for more @ Post-Bariatric Hypoglycemia Epidemiological Insights Post-Bariatric Hypoglycemia Market: Most therapies for Post-Bariatric Hypoglycemia are based on case series, case reports, or extrapolated from their use in other hypoglycemic conditions. Acarbose has been commonly used as a first-line treatment, though its effectiveness is often limited by gastrointestinal side effects. Diazoxide and octreotide have shown mixed results but are hindered by side effects and poor patient adherence. Interestingly, exogenous GLP-1 receptor agonists have demonstrated potential in improving PBH, possibly by reducing insulin secretion from β-cells and increasing glucagon secretion from α-cells during hypoglycemic episodes. Several investigational drugs, such as mizagliflozin and exendin 9-39, have shown promising results in treating PBH, offering significant improvements with well-tolerated safety profiles. With no approved therapies currently available for Post-Bariatric Hypoglycemia, there is a substantial opportunity for pharmaceutical companies to develop targeted and effective treatments for this condition. Post-Bariatric Hypoglycemia Market Insights: In 2023, the market size for Post-Bariatric Hypoglycemia in the 7MM was approximately $200 million, with growth anticipated by 2034 due to an increase in cases and the introduction of new therapies. Within the 7MM, the United States held the largest market share for Post-Bariatric Hypoglycemia in 2023, followed by France and Italy. Among emerging treatments, Eiger BioPharmaceuticals' AVEXITIDE is projected to achieve the largest market share for Post-Bariatric Hypoglycemia during the forecast period (2024–2034). Post-Bariatric Hypoglycemia Emerging Drugs Mizagliflozin: Vogenx AVEXITIDE (exendin 9-39): Eiger BioPharmaceuticals Post-Bariatric Hypoglycemia Key Companies Vogenx, Eiger BioPharmaceuticals, and others For more information, visit Post-Bariatric Hypoglycemia Market Analysis, Patient Pool, and Emerging Therapies Scope of the Post-Bariatric Hypoglycemia Market Report: 11 Years Forecast 7MM Coverage Descriptive overview of Post-Bariatric Hypoglycemia, causes, signs and symptoms, diagnosis, treatment Comprehensive insight into Post-Bariatric Hypoglycemia epidemiology in the 7MM Post-Bariatric Hypoglycemia marketed and emerging therapies Post-Bariatric Hypoglycemia companies Post-Bariatric Hypoglycemia market drivers and barriers Table of Contents: 1 Post-Bariatric Hypoglycemia Market Key Comprehensive Insights 2 Post-Bariatric Hypoglycemia Market Report Introduction 3 Competitive Intelligence Analysis for Post-Bariatric Hypoglycemia 4 Post-Bariatric Hypoglycemia Market Analysis Overview at a Glance 5 Executive Summary of Post-Bariatric Hypoglycemia 6 Post-Bariatric Hypoglycemia Epidemiology and Market Methodology 7 Post-Bariatric Hypoglycemia Epidemiology and Patient Population 8 Post-Bariatric Hypoglycemia Patient Journey 9 Post-Bariatric Hypoglycemia Treatment Algorithm, Post-Bariatric Hypoglycemia Current Treatment, and Medical Practices 10 Key Endpoints in Post-Bariatric Hypoglycemia Clinical Trials 11 Post-Bariatric Hypoglycemia Marketed Therapies 12 Post-Bariatric Hypoglycemia Emerging Therapies 13 Post-Bariatric Hypoglycemia: 7 Major Market Analysis 14 Attribute analysis 15 Access and Reimbursement Overview of Post-Bariatric Hypoglycemia 16 Post-Bariatric Hypoglycemia Market Key Opinion Leaders Reviews 18 Post-Bariatric Hypoglycemia Market Drivers 19 Post-Bariatric Hypoglycemia Market Barriers 20 SWOT Analysis 21 Disclaimer 22 DelveInsight Capabilities 23 About DelveInsight Related Reports: Post-Bariatric Hypoglycemia Epidemiology 2034 DelveInsight's "Post-Bariatric Hypoglycemia - Epidemiology Forecast to 2034" report delivers an in-depth understanding of the disease, historical and forecasted Post-Bariatric Hypoglycemia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Post-Bariatric Hypoglycemia Pipeline 2024 "Post-Bariatric Hypoglycemia Pipeline Insights, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Post-Bariatric Hypoglycemia market. A detailed picture of the Post-Bariatric Hypoglycemia pipeline landscape is provided, which includes the disease overview and Post-Bariatric Hypoglycemia treatment guidelines.
